Single-agent dabrafenib for -mutated histiocytosis.
作者信息
Bhatia Ankush, Ulaner Gary, Rampal Raajit, Hyman David M, Abdel-Wahab Omar, Durham Benjamin H, Dogan Ahmet, Ozkaya Neval, Lacouture Mario E, Hajdenberg Julio, Ganzel Chezi, Diamond Eli L
机构信息
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22.
Abstract
摘要
相似文献
1
Single-agent dabrafenib for -mutated histiocytosis.单药达拉非尼治疗 BRAF 突变型组织细胞增多症。 （你这里原文“-mutated”应该是有个具体基因名称没写全，我推测为BRAF ，你可根据实际情况调整）
Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22.
2
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations.FDA 批准概要：达拉非尼联合曲美替尼治疗携带突变的转移性非小细胞肺癌。
Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. Epub 2018 Feb 7.
3
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.BRAF 抑制剂 dabrafenib（GSK2118436）治疗转移性黑色素瘤的 II 期临床试验（BREAK-2）。
J Clin Oncol. 2013 Sep 10;31(26):3205-11. doi: 10.1200/JCO.2013.49.8691. Epub 2013 Aug 5.
4
Efficacy of Dabrafenib for three children with brainstem BRAF positive ganglioglioma.达布拉非尼治疗 3 例脑干部位 BRAF 阳性神经节胶质瘤患儿的疗效。
J Neurooncol. 2019 Oct;145(1):135-141. doi: 10.1007/s11060-019-03280-2. Epub 2019 Sep 9.
5
[Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].达拉非尼和曲美替尼用于BRAF V600E突变型儿童胶质瘤
Bull Cancer. 2024 May;111(5):429-430. doi: 10.1016/j.bulcan.2024.01.005. Epub 2024 Mar 11.
6
-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.V600E 突变性 Rosai-Dorfman-Destombes 病和朗格汉斯细胞组织细胞增生症对 BRAF 抑制剂有反应。
Blood Adv. 2019 Jun 25;3(12):1848-1853. doi: 10.1182/bloodadvances.2019000093.
7
An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.在对达拉非尼加曲美替尼耐药的BRAF V600E突变型肺腺癌中获得性NRAS Q61K突变
J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6.
8
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.实时基因组分析有助于明确组织细胞增多症的早期激酶结构域 BRAF 改变，从而改善治疗结局。
JCI Insight. 2017 Feb 9;2(3):e89473. doi: 10.1172/jci.insight.89473.
9
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.BRAF(V600E) 蛋白表达与 BRAF(V600E) 转移性黑色素瘤患者接受 BRAF 抑制剂治疗的结果。
Br J Cancer. 2013 Mar 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12.
10
Recurrent ganglioglioma in adults treated with BRAF inhibitors.接受BRAF抑制剂治疗的成人复发性神经节胶质瘤
CNS Oncol. 2016;5(1):27-9. doi: 10.2217/cns.15.40. Epub 2015 Dec 18.
引用本文的文献
1
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.荷兰和比利时组织细胞肿瘤患者靶向治疗的真实世界经验。
Blood Neoplasia. 2024 Jun 10;1(3):100023. doi: 10.1016/j.bneo.2024.100023. eCollection 2024 Sep.
2
A patient with Eradheim-Chester disease presenting with progressive cystic lung lesions and confirmed pulmonary artery hypertension: a case report.一名患有埃拉德海姆-切斯特病的患者出现进行性囊性肺病变并确诊为肺动脉高压：病例报告。
BMC Pulm Med. 2025 Mar 12;25(1):110. doi: 10.1186/s12890-024-03410-1.
3
Recent advances in therapeutic strategies of Erdheim-Chester disease.Erdheim-Chester病治疗策略的最新进展
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):6407-6428. doi: 10.1007/s00210-024-03769-2. Epub 2025 Jan 21.
4
Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim-Chester Disease.成人朗格汉斯细胞组织细胞增生症和 Erdheim-Chester 病的靶向治疗现状。
Target Oncol. 2024 Sep;19(5):691-703. doi: 10.1007/s11523-024-01080-x. Epub 2024 Jul 11.
5
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.组织细胞肿瘤患者中断靶向治疗后的结局。
Br J Haematol. 2023 Nov;203(3):389-394. doi: 10.1111/bjh.18964. Epub 2023 Jul 3.
6
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.朗格汉斯细胞组织细胞增生症和组织细胞疾病的治疗：聚焦于 MAPK 通路抑制剂。
Paediatr Drugs. 2023 Jul;25(4):399-409. doi: 10.1007/s40272-023-00569-8. Epub 2023 May 19.
7
Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.朗格汉斯细胞组织细胞增生症中的信号通路、微环境和靶向治疗。
Cell Commun Signal. 2022 Dec 19;20(1):195. doi: 10.1186/s12964-022-00917-0.
8
Experiences of a Single Center in One Hundred Ninety-Four Adult Patients With Langerhans Cell Histiocytosis.单中心194例成人朗格汉斯细胞组织细胞增多症患者的经验
J Hematol. 2022 Aug;11(4):131-141. doi: 10.14740/jh1020. Epub 2022 Aug 30.
9
Genetics and clinical phenotype of Erdheim-Chester disease: A case report of constrictive pericarditis and a systematic review of the literature.Erdheim-Chester病的遗传学与临床表型：缩窄性心包炎病例报告及文献系统综述
Front Cardiovasc Med. 2022 Aug 11;9:876294. doi: 10.3389/fcvm.2022.876294. eCollection 2022.
10
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.BRAF 加 MEK 抑制剂在 BRAF V600 突变肿瘤中的组织非特异性活性。
Mol Cancer Ther. 2022 Jun 1;21(6):871-878. doi: 10.1158/1535-7163.MCT-21-0950.
本文引用的文献
1
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.维莫非尼治疗 BRAF V600 突变型 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症：来自组织学独立、开放标签 VE-BASKET 研究的数据分析。
JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.
2
Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both and mutations.达拉非尼治疗后 Erdheim-Chester 病再次激活，伴 和 突变，使用曲美替尼治疗。
Blood. 2017 Feb 16;129(7):879-882. doi: 10.1182/blood-2016-09-740217. Epub 2016 Dec 9.
3
Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA.基于尿游离DNA指导的脑干神经组织细胞增生症的靶向治疗
Neurol Neuroimmunol Neuroinflamm. 2016 Nov 3;4(1):e299. doi: 10.1212/NXI.0000000000000299. eCollection 2017 Jan.
4
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.维莫非尼用于治疗伴有BRAF V600突变的多种非黑色素瘤癌症。
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
5
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.纪念斯隆凯特琳癌症中心可操作癌症靶点综合突变分析（MSK-IMPACT）：一种基于杂交捕获的实体瘤分子肿瘤学新一代测序临床检测方法。
J Mol Diagn. 2015 May;17(3):251-64. doi: 10.1016/j.jmoldx.2014.12.006. Epub 2015 Mar 20.
6
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.BRAF(V600E) 突变型 Erdheim-Chester 病患者应用 vemurafenib 的可重现和持续疗效。
J Clin Oncol. 2015 Feb 10;33(5):411-8. doi: 10.1200/JCO.2014.57.1950. Epub 2014 Nov 24.
7
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.系统性组织细胞增多症患者游离DNA中BRAFV600E突变检测的前瞻性盲法研究。
Cancer Discov. 2015 Jan;5(1):64-71. doi: 10.1158/2159-8290.CD-14-0742. Epub 2014 Oct 16.
8
Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.朗格汉斯细胞组织细胞增生症和 Erdheim-Chester 病与 BRAFV600E 突变相关。
Blood. 2014 Aug 14;124(7):1119-26. doi: 10.1182/blood-2013-12-543793. Epub 2014 Jun 3.
9
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.厄德里希-切斯特病诊断与临床管理的共识指南。
Blood. 2014 Jul 24;124(4):483-92. doi: 10.1182/blood-2014-03-561381. Epub 2014 May 21.
10
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.携带 BRAF V600E 突变的多系统和难治性 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症中维莫非尼的显著疗效。
Blood. 2013 Feb 28;121(9):1495-500. doi: 10.1182/blood-2012-07-446286. Epub 2012 Dec 20.
Zotero 插件